ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$6.81 USD
+0.07 (1.04%)
Updated May 3, 2024 04:00 PM ET
After-Market: $6.80 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
Brokerage Reports
ADMA Biologics Inc [ADMA]
Reports for Purchase
Showing records 41 - 60 ( 73 total )
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Top- and Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
BIVIGAM Market Re-Entry Authorized; Cash Replenished; Multiple Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
BIVIGAM Market Re-Entry Authorized; Cash Replenished; Multiple Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Credit Agreement Draw-Down Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
ASCENIV Approval Granted; Raising Target to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Awaiting FDA Response on BIVIGAM; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
New Credit Agreement Implemented; Less Onerous Debt Terms; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Slowly but Surely Making a Comeback; Assuming Coverage at Buy and $10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
All Systems Are Go as ADMA Reports 3Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Initiating Coverage With a Buy Rating and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J